Elekta AB (OTCMKTS:EKTAY) Short Interest Update

Elekta AB (OTCMKTS:EKTAY) saw a significant decrease in short interest in the month of April. As of April 30th, there was short interest totaling 669 shares, a decrease of 53.3% from the April 15th total of 1,433 shares. Based on an average daily volume of 1,312 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.0% of the company’s stock are short sold.

Elekta Price Performance

OTCMKTS EKTAY remained flat at $6.05 on Friday. The company had a trading volume of 84 shares, compared to its average volume of 620. The stock has a market capitalization of $2.23 billion, a PE ratio of -603.96 and a beta of 1.01. The business has a 50-day moving average price of $6.01 and a two-hundred day moving average price of $5.90. Elekta has a twelve month low of $4.35 and a twelve month high of $6.93. The company has a quick ratio of 0.73, a current ratio of 0.95 and a debt-to-equity ratio of 0.56.

Elekta (OTCMKTS:EKTAY) last released its quarterly earnings results on Thursday, March 5th. The company reported $0.09 EPS for the quarter. The business had revenue of $433.29 million during the quarter. Elekta had a positive return on equity of 12.84% and a negative net margin of 0.08%. On average, research analysts expect that Elekta will post 0.39 EPS for the current year.

Elekta Company Profile

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.